Qube Research & Technologies (QRT)’s Apellis Pharmaceuticals APLS Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-18,843	Closed	-$473K	–	3519
2025 Q4	$473K	Sell	18,843 -101,160	-84%	-$2.37M	﹤0.01%	2820
2025 Q3	$2.72M	Buy	+120,003	New	+$2.8M	﹤0.01%	2085
2024 Q4	–	Sell	-27,948	Closed	-$806K	–	3432
2024 Q3	$806K	Buy	+27,948	New	+$1.04M	﹤0.01%	2108
2024 Q2	–	Sell	-8,481	Closed	-$499K	–	3779
2024 Q1	$499K	Buy	+8,481	New	+$541K	﹤0.01%	2536
2023 Q3	–	Sell	-94,783	Closed	-$8.63M	–	4072
2023 Q2	$8.63M	Buy	+94,783	New	+$8.18M	0.03%	573
2021 Q3	–	Sell	-3,915	Closed	-$247K	–	2169
2021 Q2	$247K	Buy	+3,915	New	+$202K	﹤0.01%	1690

Other funds holding APLS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Qube Research & Technologies (QRT)'s APLS Position: Q1 2026 in Review

Qube Research & Technologies (QRT) sold out of Apellis Pharmaceuticals (APLS) in Q1 2026, closing a stake of 18,843 shares — an estimated $473K sold.

Qube Research & Technologies (QRT) first reported a position in APLS in Q2 2021 and held it in 6 quarters. The position peaked at $8.63M in Q2 2023. 323 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

Qube Research & Technologies (QRT) reported no remaining Apellis Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Qube Research & Technologies (QRT) sold 18,843 Apellis Pharmaceuticals shares in Q1 2026, an estimated $473K.
Qube Research & Technologies (QRT) first reported a position in Apellis Pharmaceuticals in Q2 2021 and held it in 6 quarters.
Qube Research & Technologies (QRT)'s Apellis Pharmaceuticals position peaked at $8.63M in Q2 2023.
323 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q1 2026, filed 15 May 2026.